Adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypotension · AKI
Early leads to higher adverse events: hypotension compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Diarrhoea · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Diarrhoea ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Side effects or other adverse events · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in adverse events/side effects compared with placebo (high certainty).
1 finding from 1 review
Adverse events To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events To discharge · newborn infants with opioid withdrawal
1 finding from 1 review
Adverse events To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Study reports · adults with Major Depressive Disorder
It is very uncertain whether n3PUFAs changes adverse eventsStudy reports compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (4 to 6‐week · primary Raynaud's phenomenon
Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ depression · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ depression compared with placebo (very low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review
All reported adverse events · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All reported adverse events · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All reported adverse events · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All reported adverse events · pressure ulcer prevention
1 finding from 1 review
All reported adverse events · pressure ulcer prevention
1 finding from 1 review
All reported adverse events · pressure ulcer prevention
1 finding from 1 review